Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefebvre S, Thauvette L, Gauthier J, Goulet S, Poupar. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatiti. J. Biol. Chem. . 2005. 280. 39260-39267. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009. 49(4). 1069-1082. Find at Google Scholar.
Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F. . Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA. Virol J. . 2013. 10. 355. Find at Google Scholar.
Trevino A, de Mendoza C, Parra P, Rodriguez C, Madejan A, Plaza Z, del Romero J, Poveda E, Soriano V. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HI. Antivir Ther. . 2011. 16(3). 413-416. Find at Google Scholar.